Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Res, 75(12), 2489-500. presented at the 2015 Jun 15. doi:10.1158/0008-5472.CAN-14-3167
. (2015).